Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/21/24
End: 02/28/26
Due: 02/28/27
Phase: N/A
Priority: Normal
Start: 03/17/25
End: 03/31/27
Due: 03/31/28
Phase: N/A
Priority: Normal
Start: 04/16/24
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 06/24/24
End: 06/30/25
Due: 06/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation | NCT06706388 | n-Lorem Foundation | user2@example.com | None | 2024-02-21 | 2026-02-28 | 2027-02-28 | - | - | 2025-07-14 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD) | NCT06816498 | n-Lorem Foundation | user2@example.com | None | 2025-03-17 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS | NCT06392126 | n-Lorem Foundation | user2@example.com | None | 2024-04-16 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |
| Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS | NCT06977451 | n-Lorem Foundation | user2@example.com | None | 2024-06-24 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |